Age-related brain parenchymal fraction is significantly decreased in young multiple sclerosis patients: a quantitative MRI study

Neuroreport ◽  
2003 ◽  
pp. 427-430 ◽  
Author(s):  
Jan Kassubek ◽  
Hayrettin Tumani ◽  
Daniel Ecker ◽  
Anja Kurt ◽  
Albert C. Ludolph ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Quantitative Mri ◽  
Age Related ◽  
Brain Parenchymal Fraction ◽  
Brain Parenchymal ◽  
Multiple Sclerosis Patients ◽  
Mri Study

A 24-month advanced magnetic resonance imaging study of multiple sclerosis patients treated with alemtuzumab

2018 ◽  
Vol 25 (6) ◽  
pp. 811-818 ◽  
Author(s):  
Irene M Vavasour ◽  
Roger Tam ◽  
David KB Li ◽  
Cornelia Laule ◽  
Carolyn Taylor ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Magnetic Resonance ◽  
Cortical Thickness ◽  
Diffusion Tensor ◽  
Imaging Study ◽  
Water Fraction ◽  
Normal Appearing White Matter ◽  
Brain Parenchymal Fraction ◽  
Brain Parenchymal ◽  
Multiple Sclerosis Patients

Background: Tissue damage in both multiple sclerosis (MS) lesions and normal-appearing white matter (NAWM) are important contributors to disability and progression. Specific aspects of MS pathology can be measured using advanced imaging. Alemtuzumab is a humanised monoclonal antibody targeting CD52 developed for MS treatment. Objective: To investigate changes over 2 years of advanced magnetic resonance (MR) metrics in lesions and NAWM of MS patients treated with alemtuzumab. Methods: A total of 42 relapsing–remitting alemtuzumab-treated MS subjects were scanned for 2 years at 3 T. T1 relaxation, T2 relaxation, diffusion tensor, MR spectroscopy and volumetric sequences were performed. Mean T1 and myelin water fraction (MWF) were determined for stable lesions, new lesions and NAWM. Fractional anisotropy was calculated for the corpus callosum (CC) and N-acetylaspartate (NAA) concentration was determined from a large NAWM voxel. Brain parenchymal fraction (BPF), cortical thickness and CC area were also calculated. Results: No change in any MR measurement was found in lesions or NAWM over 24 months. BPF, cortical thickness and CC area all showed decreases in the first year followed by stability in the second year. Conclusion: Advanced MR biomarkers of myelin (MWF) and neuron/axons (NAA) show no change in NAWM over 24 months in alemtuzumab-treated MS participants.

Frontal parenchymal atrophy measures in multiple sclerosis

2004 ◽  
Vol 10 (5) ◽  
pp. 562-568 ◽  
Author(s):  
Laura Locatelli ◽  
Robert Zivadinov ◽  
Attilio Grop ◽  
Marino Zorzon
Keyword(s):  
Multiple Sclerosis ◽  
Cognitive Functions ◽  
Brain Atrophy ◽  
Neuropsychological Functioning ◽  
Intraclass Correlation ◽  
Quantitative Mri ◽  
Cross Sectional ◽  
Regional Brain ◽  
Brain Parenchymal Fraction ◽  
Brain Parenchymal

The aim of this study was to establish whether, in a cross-sectional study, the normalized measures of whole and regional brain atrophy correlate better with tests assessing the cognitive function than the absolute brain atrophy measures. The neuropsychological performances and disability have been assessed in 39 patients with relapsing-remitting multiple sclerosis (MS). T1- and T2-lesion load (LL) of total brain and frontal lobes (FLs) were measured using a reproducible semiautomated technique. The whole brain volume and the regional brain parenchymal volume (RBPV) of FLs were obtained using a computerized interactive program, which incorporates semiautomated and automated segmentation processes. Normalized measures of brain atrophy, i.e., brain parenchymal fraction (BPF) and regional brain parenchymal fraction (RBPF) of FLs, were calculated. The scan-rescan, inter- and intrarater coefficient of variation (COV) and intraclass correlation coefficient (ICC) have been estimated. The RBPF of FLs showed an acceptable level of reproducibility which ranged from 1.7% for intrarater variability to 3.2% for scan-rescan variability. The mean ICC was 0.88 (CI 0.82-0.93). The RBPF of FLs demonstrated stronger magnitudes of correlation with neuropsychological functioning, disability and quantitative MRI lesion measures than RBPV. These differences were statistically significant: P=0.001 for Stroop Color Word Interference test, P=0.001 for Paced Auditory Serial Addition Test, P=0.04 for Standard Raven Progressive Matrices, P=0.049 for Expanded Disability Status Scale, P=0.01 for T2-LL of FLs and P< 0.001 for T1-LL of FLs. BPF demonstrated significant correlations with tests assessing cognitive functions, whereas BPAV did not. The correlation analysis results were supported by the results of multiple regression analysis which showed that only the normalized brain atrophy measures were associated with tests exploring the cognitive functions. These data suggest that RBPF is a reproducible and sensitive method for measuring frontal parenchymal atrophy. The normalized measures of whole and regional brain parenchymal atrophy should be preferred to absolute measures in future studies that correlate neuropsychological performances and brain atrophy measures in patients with MS.

scholarly journals Smartphone-Based Symbol-Digit Modalities Test Reliably Measures Cognitive Function in Multiple Sclerosis Patients

2020 ◽  
Author(s):  
Linh Pham ◽  
Thomas Harris ◽  
Mihael Varosanec ◽  
Peter Kosa ◽  
Bibiana Bielekova
Keyword(s):  
Multiple Sclerosis ◽  
Cognitive Processing ◽  
Processing Speed ◽  
Test Performance ◽  
Relevant Information ◽  
Imaging Features ◽  
Speed Test ◽  
Brain Parenchymal Fraction ◽  
Brain Parenchymal ◽  
Multiple Sclerosis Patients

AbstractLimited time for patient encounters prevents reliable evaluation of all neurological functions in routine clinical practice. Quantifying neurological disability in a patient-autonomous manner via smartphones may remedy this problem, if such tests provide reliable, disease-relevant information.We developed a smartphone version of the cognitive processing speed test, the Symbol-Digit Modalities Test (SDMT), and assessed its clinical utility. The traditional SDMT uses identical symbol-number codes, allowing memorization after repeated trials. In the phone app, the symbol-number codes are randomly generated.In 154 multiple sclerosis (MS) patients and 39 healthy volunteers (HV), traditional and smartphone SDMT have good agreement (Lin’s coefficient of concordance [CCC] = 0.84) and comparable test-retest variance. In subjects with available volumetric MRI and digitalized neurological examinations (112 MS, 12 HV), the SDMT scores were highly associated with T2 lesion load and brain parenchymal fraction, when controlled for relevant clinical characteristics. The smartphone SDMT association with clinical/imaging features was stronger (R2 = 0.75, p < 0.0001) than traditional SDMT (R2 = 0.65, p < 0.0001). In the longitudinal subcohort, improvements from testing repetition (learning effects), were identifiable using non-linear regression in 14/16 subjects and, on average, peaked after 8 trials. Averaging several post-learning SDMT results significantly lowers the threshold for detecting true decline in test performance.In conclusion, smartphone, self-administered SDMT is a reliable substitute of the traditional SDMT for measuring processing speed in MS patients. Granular measurements at home increase sensitivity to detect true performance decline in comparison to sporadic assessments in the clinic.

Has your patient's multiple sclerosis lesion burden or brain atrophy actually changed?

2004 ◽  
Vol 10 (4) ◽  
pp. 402-406 ◽  
Author(s):  
Xingchang Wei ◽  
Charles RG Guttmann ◽  
Simon K Warfield ◽  
Michael Eliasziw ◽  
J Ross Mitchell
Keyword(s):  
Multiple Sclerosis ◽  
Measurement Error ◽  
Brain Tissue ◽  
Brain Atrophy ◽  
Multiple Sclerosis Lesion ◽  
Lesion Volume ◽  
Measurement Variability ◽  
Brain Parenchymal Fraction ◽  
Significant Change ◽  
Brain Parenchymal

Changes in mean magnetic resonance imaging (MRI)-derived measurements between patient groups are often used to determine outcomes in therapeutic trials and other longitudinal studies of multiple sclerosis (MS). However, in day-to-day clinical practice the changes withinindividual patients may also be of interest. In this paper, we estimated the measurement error of an automated brain tissue quantification algorithm and determined the thresholds for statistically significant change of MRI-derived T2 lesion volume and brain atrophy in individual patients. Twenty patients with MS were scanned twice within 30 min. Brain tissue volumes were measured using the computer algorithm. Brain atrophy was estimated by calculation of brain parenchymal fraction. The threshold of change between repeated scans that represented statistically significant change beyond measurement error with 95% certainty was 0.65 mL for T2 lesion burden and 0.0056 for brain parenchymal fraction. Changes in lesion burden and brain atrophy below these thresholds can be safely (with 95% certainty) explained by measurement variability alone. These values provide clinical neurologists with a useful reference to interpret MRI-derived measures in individual patients.

scholarly journals Automated Determination of Brain Parenchymal Fraction in Multiple Sclerosis

2012 ◽  
Vol 34 (3) ◽  
pp. 498-504 ◽  
Author(s):  
M. Vågberg ◽  
T. Lindqvist ◽  
K. Ambarki ◽  
J.B.M. Warntjes ◽  
P. Sundström ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Brain Parenchymal Fraction ◽  
Brain Parenchymal ◽  
Automated Determination

Infratentorial lesion volume correlates with sensory functional system in multiple sclerosis patients: a 3.0-Tesla MRI study

2009 ◽  
Vol 115 (1) ◽  
pp. 115-124 ◽  
Author(s):  
C. C. Quattrocchi ◽  
A. Cherubini ◽  
G. Luccichenti ◽  
M. G. Grasso ◽  
U. Nocentini ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Functional System ◽  
Lesion Volume ◽  
3.0 Tesla ◽  
Multiple Sclerosis Patients ◽  
Mri Study

Chromatic discrimination losses in multiple sclerosis patients with and without optic neuritis using the Cambridge Colour Test

2008 ◽  
Vol 25 (3) ◽  
pp. 463-468 ◽  
Author(s):  
ANA LAURA DE ARAÚJO MOURA ◽  
ROSANI APARECIDA ANTUNES TEIXEIRA ◽  
NESTOR N. OIWA ◽  
MARCELO F. COSTA ◽  
CLAUDIA FEITOSA-SANTANA ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Optic Neuritis ◽  
Color Vision ◽  
Color Discrimination ◽  
Demyelinating Diseases ◽  
Color Test ◽  
Age Related ◽  
History Of ◽  
Patient Groups ◽  
Multiple Sclerosis Patients

We assessed chromatic discrimination in multiple sclerosis (MS) patients both with (ON) and without (no ON) a history of optic neuritis using the Cambridge color test (CCT). Our goal was to determine the magnitude and chromatic axes of any color vision losses in both patient groups, and to evaluate age-related changes in chromatic discrimination in both patient groups compared to normals. Using the CCT, we measured chromatic discrimination along the protan, deutan and tritan axes in 35 patients with MS (17 ON eyes) and 74 age matched controls. Color thresholds for both patient groups were significantly higher than controls' along the protan and tritan axes (p < 0.001). In addition, the ON and no-ON groups differed significantly along all three-color axes (p < 0.001). MS patients presented a progressive color discrimination impairment with age (along the deutan and tritan axes) that was almost two times faster than controls, even in the absence of ON. These findings suggest that demyelinating diseases reduce sensitivity to color vision in both red-green and blue-yellow axes, implying impairment in both parvocellular and koniocellular visual pathways. The CCT is a useful tool to help characterize vision losses in MS, and the relationship between these losses and degree of optic nerve involvement.

Sign in / Sign up

Export Citation Format

Share Document